Global PET Radiopharmaceuticals Market Size By Type (F-18, Ru-82), By Application (Oncology, Cardiology), By Region, And Segment Forecasts, 2023 to 2032

The Global PET Radiopharmaceuticals Market was valued at USD 2.3 billion in 2023 and is projected to reach USD 4.9 billion by 2031, growing at a CAGR of 9.7% during the forecast period from 2023 to 2031. The market is experiencing robust growth due to rising incidences of cancer and neurological disorders, increasing demand for advanced diagnostic imaging techniques, and the expanding use of positron emission tomography (PET) for early and precise disease detection. The integration of PET imaging in clinical practices has significantly improved the accuracy of diagnostics, thereby accelerating the demand for PET radiopharmaceuticals globally.

Drivers:

1. Rising Incidence of Chronic Diseases:

A growing global burden of diseases such as cancer, Alzheimer’s, and cardiovascular disorders is significantly boosting the demand for PET imaging, which in turn fuels the consumption of PET radiopharmaceuticals for timely and accurate diagnosis.

2. Advancements in Radiotracer Technology:

Ongoing R&D in nuclear medicine has led to the development of new radiotracers with higher specificity and shorter half-lives, enabling better imaging results and patient safety, which further supports market growth.

3. Expansion of Nuclear Medicine Infrastructure:

The proliferation of cyclotrons and radiopharmacies in hospitals and diagnostic centers, especially in emerging economies, is enhancing the accessibility and availability of PET radiopharmaceuticals.

Restraints:

1. High Cost of PET Imaging Procedures:

The high cost associated with PET scans and radiopharmaceuticals can be a major barrier, particularly in low- and middle-income countries. Reimbursement challenges also pose constraints to wider market adoption.

2. Regulatory and Logistical Challenges:

Strict regulations governing radioactive materials and the short shelf life of PET tracers create complexities in production, distribution, and storage, which may hinder the market's operational efficiency.

Opportunity:

1. Growth in Oncology Diagnostics:

PET radiopharmaceuticals are widely used in oncology for tumor detection, staging, and therapy monitoring. With cancer cases on the rise, particularly in Asia-Pacific and Latin America, the market stands to gain significantly from increased diagnostic demand.

2. Technological Integration and AI Advancements:

Integration of artificial intelligence with PET imaging for real-time image processing, along with hybrid PET/MRI systems, opens new opportunities for precision diagnostics and personalized treatment strategies.

Market by System Type Insights:

Based on system type, Fluorodeoxyglucose (FDG) radiopharmaceuticals accounted for the largest market share in 2023. FDG continues to be the most widely used PET radiotracer, primarily in oncology imaging due to its effectiveness in highlighting metabolic activity. Meanwhile, non-FDG tracers such as Ga-68 and F-18 labeled compounds are expected to witness significant growth, driven by their rising use in neurology and cardiology imaging.

Market by End-use Insights:

By end use, Hospitals and Diagnostic Imaging Centers dominated the market in 2023, owing to their comprehensive infrastructure, access to cyclotrons, and availability of skilled personnel. This segment is expected to maintain its lead due to increasing healthcare spending and the growing prevalence of chronic diseases requiring PET imaging. Research Institutes are also showing steady growth, supported by expanding clinical trials and pharmaceutical R&D investments.

Market by Regional Insights:

Regionally, North America held the largest share in 2023 due to a well-established healthcare infrastructure, early adoption of advanced diagnostic tools, and the presence of major radiopharmaceutical manufacturers. Asia-Pacific is projected to register the fastest growth during the forecast period, driven by rising healthcare investments, government support for nuclear medicine, and increasing disease burden in countries such as China and India.

Competitive Scenario:

Key players in the Global PET Radiopharmaceuticals Market include GE Healthcare, Siemens Healthineers, Cardinal Health, Lantheus Medical Imaging, Jubilant Radiopharma, Curium Pharma, Advanced Accelerator Applications (Novartis), Bracco Imaging, and Nordion (Canada) Inc. These companies are focusing on expanding their radiopharmaceutical product pipelines, forming strategic alliances, and investing in regional distribution networks.

Key Market Developments:

In 2024, GE Healthcare launched a next-generation cyclotron system optimized for high-purity PET tracer production in emerging markets.

Curium Pharma announced an agreement in 2023 with a major US health system to supply novel PET tracers for brain imaging.

Lantheus Medical Imaging received FDA approval in 2023 for a new PSMA-targeted PET agent used in prostate cancer detection.

Scope of Work – Global PET Radiopharmaceuticals Market

Report Metric Details

Market Size (2023) USD 2.3 Billion

Projected Market Size (2031) USD 4.9 Billion

CAGR (2023–2031) 9.7%

Market Segments By System Type (FDG, Non-FDG), By End-use (Hospitals, Diagnostic Centers, Research Institutes)

Growth Drivers Rising chronic disease burden, Technological advances in tracers, Expansion of nuclear medicine infrastructure

Opportunities Increased oncology applications, AI-enhanced imaging, Emerging market expansion

FAQs

1) What is the current market size of the Global PET Radiopharmaceuticals Market?

The Global PET Radiopharmaceuticals Market was valued at USD 2.3 billion in 2023.

2) What is the major growth driver of the Global PET Radiopharmaceuticals Market?

The market is primarily driven by the rising incidence of chronic diseases such as cancer and neurological disorders, boosting the demand for precise diagnostic imaging.

3) Which is the largest region during the forecast period in the Global PET Radiopharmaceuticals Market?

North America is the largest regional market, supported by advanced healthcare infrastructure and early adoption of PET imaging technologies.

4) Which segment accounted for the largest market share in the Global PET Radiopharmaceuticals Market?

The FDG (fluorodeoxyglucose) radiopharmaceutical segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global PET Radiopharmaceuticals Market?

Key players include GE Healthcare, Siemens Healthineers, Cardinal Health, Curium Pharma, Lantheus Medical Imaging, and Jubilant Radiopharma.